Journal article · 2026 · Open access

Enhancing Safety Signaling: Integrating Clinical Trials and Post-Marketing Adverse Event Reports

Fernanda Bravo, Lawrence Yunliang Chen, John Silberholz

Manufacturing & Service Operations Management · Published 16 October 2026 · DOI 10.1287/msom.2024.0890

Open full textView at the publisherCite this paper

In brief

“Enhancing Safety Signaling: Integrating Clinical Trials and Post-Marketing Adverse Event Reports” is a 2026 journal article by Fernanda Bravo and 2 co-authors, published in Manufacturing & Service Operations Management. OpenAlex counts 1 citations as of 16 November 2026, which puts it in the top 9% of works published in 2026 by citations. It is open access: the full text is free to read at SSRN Electronic Journal.

Citations
1
Most cited in
2026 (1)
Field-weighted impact
3.20
References
49
Authors
3

Abstract

Problem definition: Adverse drug reactions (ADRs) cause numerous emergency room visits and thousands of deaths annually in the U.S. Although regulators like the Food and Drug Administration (FDA) aim to detect safety issues during clinical trials, these trials are often too small, short, or restrictive to capture rare or delayed ADRs. Consequently, regulators rely on spontaneous adverse event reporting systems (eg, FAERS) to identify potential safety issues—termed safety signals—by detecting side effects that occur disproportionately among patients taking a particular drug. However, these observational data are subject to selection and reporting biases, which can lead to false signals or missed risks. Methodology/results: We propose a Bayesian framework to enhance the hypothesis generation step in safety signaling, offering two methodological advances over standard approaches that rely solely on observational data. First, it integrates pre-approval clinical trial and post-approval observational data. Second, it uses information from common ADRs to estimate and correct bias in rare ADRs. We assess the approach using an analytical model and a large-scale numerical study with real clinical trial and FAERS data. Incorporating clinical trial data substantially reduces signaling costs, and using a common ADR for debiasing yields further gains. This refinement improves decisions for about 1% of ADRs, translating to expected cost savings of 1.5–2.3% (approx. $32–159 million), with performance robust to moderate parameter misspecification. Managerial implications: By using existing regulatory data, our approach supports a more efficient and timely hypothesis generation process in post-approval surveillance.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Bravo, F., Chen, L. Y., & Silberholz, J. (2026). Enhancing Safety Signaling: Integrating Clinical Trials and Post-Marketing Adverse Event Reports. Manufacturing & Service Operations Management. https://doi.org/10.1287/msom.2024.0890

MLA 9

Bravo, Fernanda, et al. “Enhancing Safety Signaling: Integrating Clinical Trials and Post-Marketing Adverse Event Reports.” Manufacturing & Service Operations Management, 2026. https://doi.org/10.1287/msom.2024.0890.

Chicago

Bravo, Fernanda, Lawrence Yunliang Chen, and John Silberholz. 2026. “Enhancing Safety Signaling: Integrating Clinical Trials and Post-Marketing Adverse Event Reports.” Manufacturing & Service Operations Management. https://doi.org/10.1287/msom.2024.0890.

Harvard

Bravo, F., Chen, L. Y. and Silberholz, J. (2026) ‘Enhancing Safety Signaling: Integrating Clinical Trials and Post-Marketing Adverse Event Reports’, Manufacturing & Service Operations Management. doi:10.1287/msom.2024.0890.

IEEE

F. Bravo, L. Y. Chen, and J. Silberholz, “Enhancing Safety Signaling: Integrating Clinical Trials and Post-Marketing Adverse Event Reports,” Manufacturing & Service Operations Management, 2026, doi: 10.1287/msom.2024.0890.

BibTeX

@article{bravo2026enhancing,
  title     = {{Enhancing Safety Signaling: Integrating Clinical Trials and Post-Marketing Adverse Event Reports}},
  author    = {Bravo, Fernanda and Chen, Lawrence Yunliang and Silberholz, John},
  journal   = {Manufacturing \& Service Operations Management},
  year      = {2026},
  doi       = {10.1287/msom.2024.0890},
  url       = {https://doi.org/10.1287/msom.2024.0890}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions

  • safety signals
  • adverse drug reactions
  • spontaneous adverse event reporting
  • FDA Adverse Event Reporting System
  • clinical trial data integration
  • post-marketing surveillance
  • reporting bias
  • selection bias

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Bravo, F., Chen, L. Y., & Silberholz, J. (2026). Enhancing Safety Signaling: Integrating Clinical Trials and Post-Marketing Adverse Event Reports. Manufacturing & Service Operations Management. https://doi.org/10.1287/msom.2024.0890

How many times has this paper been cited?

1 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at SSRN Electronic Journal: sign in and open the full text from this page.

Who wrote this paper?

Fernanda Bravo, Lawrence Yunliang Chen, John Silberholz.

What is the DOI of this paper?

10.1287/msom.2024.0890, permanently at https://doi.org/10.1287/msom.2024.0890. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.